MEDTRONIC SPINE SALES DECLINE – WAITING FOR INFUSE AND KYPHOPLASTY (Orthopedics This Week)
Medtronic Inc.’s overall spine sales declined by 2% to $786 million during the company’s previous quarter.
During a call with Wall Street analysts on May 20, 2014, company leaders said with core spine sales growing, they are counting on the stabilization of kyphoplasty and Infuse to get them back to overall growth.
Core Spine Business Growing
Excluding sales of balloon kyphoplasty (BKP), company management reported that its core spine business grew by 1% to $662 million in a spine market that remained re...
The Orthopedics Industry 